EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA

Amanda Frydendahl iD, Mads Heilskov Rasmussen iD, Sarah Østrup Jensen iD, Tenna Vesterman Henriksen, Christina Demuth, Mathilde Diekema, Henrik Jørn Ditzel iD, Sara Witting Christensen Wen iD, Jakob Skou Pedersen, Lars Dyrskjøt, Claus Lindbjerg Andersen iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25084252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Amanda Frydendahl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA, High-Throughput Nucleotide Sequencing, Biomarkers, Tumor. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, NEYE Foundation, Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) is a promising biomarker, reflecting the presence of tumor cells. Sequencing-based detection of ctDNA at low tumor fractions is challenging due to the crude error rate of sequencing. To mitigate this challenge, we developed ultra-deep mutation-integrated sequencing (UMIseq), a fixed-panel deep targeted sequencing approach, which is universally applicable to all colorectal cancer (CRC) patients. UMIseq features UMI-mediated error correction, the exclusion of mutations related to clonal hematopoiesis, a panel of normal samples for error modeling, and signal integration from single-nucleotide variations, insertions, deletions, and phased mutations. UMIseq was trained and independently validated on pre-operative (pre-OP) plasma from CRC patients (n = 364) and healthy individuals (n = 61). UMIseq displayed an area under the curve surpassing 0.95 for allele frequencies (AFs) down to 0.05%. In the training cohort, the pre-OP detection rate reached 80% at 95% specificity, while it was 70% in the validation cohort. UMIseq enabled the detection of AFs down to 0.004%. To assess the potential for detection of residual disease, 26 post-operative plasma samples from stage III CRC patients were analyzed. From this we found that the detection of ctDNA was associated with recurrence. In conclusion, UMIseq demonstrated robust performance with high sensitivity and specificity, enabling the detection of ctDNA at low allele frequencies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCirculating Tumor DNAHigh-Throughput Nucleotide SequencingBiomarkers, TumorMutationHumansMaleFemaleAgedMiddle AgedAdultGene FrequencyAged, 80 and overCell-Free Nucleic AcidsSensitivity and Specificity

Stichwörter der Autor:innen

DNA mutationUMI-mediated error suppressioncell-free tumor DNAcfDNAclonal hematopoiesiscolorectal cancerctDNAliquid biopsyminimal residual diseasenext-generation sequencing

Substanzen

Circulating Tumor DNABiomarkers, TumorCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.
  • Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark.
  • Department of Oncology, Odense University Hospital, 5000 Odense, Denmark.
  • Department of Oncology, Lillebaelt Hospital, 7100 Vejle, Denmark.
  • Bioinformatics Research Center, Faculty of Science, Aarhus University, 8000 Aarhus, Denmark.

ORCID-Profile: Amanda Frydendahl, Mads Heilskov Rasmussen, Sarah Østrup Jensen, Henrik Jørn Ditzel, Sara Witting Christensen Wen, Claus Lindbjerg Andersen

Förderung

  • Cancer Research UK
  • NEYE Foundation
  • Novo Nordisk Foundation
  • Danish Cancer Society

Zitieren

APA

Frydendahl, A., Rasmussen, M. H., Jensen, S. Ø., Henriksen, T. V., Demuth, C., Diekema, M., Ditzel, H. J., Wen, S. W. C., Pedersen, J. S., Dyrskjøt, L., & Andersen, C. L. (2024). Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084252

Vancouver

Frydendahl A, Rasmussen MH, Jensen SØ, Henriksen TV, Demuth C, Diekema M, et al. Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084252

BibTeX
@article{Frydendahl2024,
  author = {Frydendahl, Amanda and Rasmussen, Mads Heilskov and Jensen, Sarah Østrup and Henriksen, Tenna Vesterman and Demuth, Christina and Diekema, Mathilde and Ditzel, Henrik Jørn and Wen, Sara Witting Christensen and Pedersen, Jakob Skou and Dyrskjøt, Lars and Andersen, Claus Lindbjerg},
  title = {Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25084252}
}
Kostenlos starten →